Amerikanische Gesellschaft für Hirudotherapie

Comparison of outcomes of arterial end-to-side versus end-to-end anastomosis in autologous deep inferior epigastric perforator (DIEP) flap breast reconstruction: DIEP-ES study protocol.

Research article published in International journal of surgery protocols (2025)

Zuletzt aktualisiert: June 18, 2026Geprüft von: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportKlinische StudienArzneimittelentwicklungDidzun et al. · International journal of surgery protocols, 2025

Abstract

BACKGROUND: End-to-end anastomosis to the internal mammary artery (IMA) is the current standard anastomosis technique for women undergoing autologous breast reconstruction with deep inferior epigastric perforator (DIEP) flap. This approach fails to preserve the length of the IMA, compromising its availability for cardiac surgery use in women who develop coronary heart disease. A viable alternative may be end-to-side anastomosis, but data on its feasibility is currently lacking. METHODS: This pilot study will involve 60 patients at a single-center institute over approximately 24 months. Inclusion criteria are female sex, age >18 years, history of breast cancer, and eligibility for unilateral autologous DIEP breast reconstruction. Exclusion criteria include patients with a legal guardian, inability to consent, and history of blood clotting disorders or hypercoagulability. Data will be collected at 2 weeks, 6 weeks, 6 months, and 1-year post-surgery. The primary outcome is "major complication" of the recipient site, including anastomotic insufficiency, arterial thrombosis, hematoma, reoperation, or flap loss. Secondary outcomes are abdominal perfusion and major donor site complications, such as wound healing disorders. Patient satisfaction will be assessed using the SF-36 and BREAST-Q (reconstructive module) questionnaires. STUDY STATUS: The DIEP-ES study has begun enrolment in February 2023. As this is an ongoing trial, no results have been gathered yet. The results will be reported upon completion of the study. We anticipate that the primary and secondary outcomes of the end-to-side approach will be comparable to the accepted standard of care, i.e., end-to-end anastomoses. CONCLUSIONS: End-to-side anastomosis may be a safe alternative for DIEP breast reconstruction, especially for patients at risk for coronary heart disease. This pilot study aims to evaluate the feasibility and safety of the end-to-side anastomosis technique in DIEP-flap breast reconstruction. The preliminary findings will inform the design of future multicentric trials to confirm the efficacy of this approach.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Zusammenfassung

End-to-end anastomosis to the internal mammary artery (IMA) is the current standard anastomosis technique for women undergoing autologous breast reconstruction with deep inferior epigastric perforator (DIEP) flap. This approach fails to preserve the length of the IMA, compromising its availability...

Warum dies für die Hirudotherapie relevant ist

This article is a study protocol for a planned 60-patient pilot evaluating end-to-side arterial anastomosis in unilateral autologous DIEP flap breast reconstruction, with primary outcomes including major recipient-site complications such as anastomotic insufficiency, arterial thrombosis, hematoma, reoperation, or flap loss; enrollment began in February 2023 and no results were available. The protocol focuses on surgical technique feasibility and safety, and anticipates comparing outcomes with the standard end-to-end approach once complete. It does not mention leeches, hirudotherapy, or the leech secretome. Therefore, it offers no direct evidence for hirudotherapy, and no leech-therapy connection is supported by the abstract.

Zitation

Comparison of outcomes of arterial end-to-side versus end-to-end anastomosis in autologous deep inferior epigastric perforator (DIEP) flap breast reconstruction: DIEP-ES study protocol.

Didzun et al. · International journal of surgery protocols, 2025

Verwandter klinischer Kontext

Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.